We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Renishaw Launches RenDx® Multiplex Assay System and Fungiplex Assay

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Renishaw Diagnostics has announced the launch of the CE-IVD certified RenDx Multiplex Assay System together with its first assay, Fungiplex, a multiplex PCR in vitro test for the qualitative detection of Candida and Aspergillus DNA extracted from blood samples.

The assay is designed for use on the RenDx Multiplex Assay System, an automation and detection platform that allows processing of up to 45 samples in a single run and identifies 12 Candida and Aspergillus species using a unique detection technology known as surface enhanced resonance Raman spectroscopy (SERRS).

Rupert Jones, General Manager of Renishaw Diagnostics, said, “The CE-IVD launch of our RenDx platform and first assay marks a significant milestone, not just in the progress made here at Renishaw Diagnostics but more importantly, for infectious disease diagnostics throughout Europe. The extensive target menu for the Fungiplex assay, together with the high sensitivity that can be achieved through our exceptional detection technology, has the potential to aid earlier diagnosis, reduce overall spend and improve patient outcomes for those susceptible to these life threatening infections. We are looking forward to working with clinicians and laboratories to bring this assay into routine clinical use.”